Table 1 Baseline characteristics of patients with osteoporotic fracture according to BC diagnosis (n=1193)
Variable | BC (n=62) | No BC (n=1,131) | P value |
|---|---|---|---|
Age at first fracture | 68.8 (±8.8) | 68.8 (±10.2) | 0.969a |
BMI | 29.3 (±4.8) | 29.6 (±5.6) | 0.735a |
BMI | |||
⩽30 | 39 (62.9) | 637 (56.3) | 0.658b |
30.1–35 | 15 (24.2) | 309 (27.3) | |
35.1–40 | 7 (11.3) | 139 (12.3) | |
⩾40.1 | 1 (1.6) | 46 (4.1) | |
BMD, g/cm 2 | |||
Femoral neck | 0.77 (±0.11) | 0.76 (±0.12) | 0.317a |
Total hip | 0.84 (±0.13) | 0.82 (±0.13) | 0.164a |
Spine | 0.96 (±0.15) | 0.95 (±0.16) | 0.450a |
BMD T-score | |||
Femoral neck | −1.72 (±0.94) | −1.85 (±1.00) | 0.330a |
Total hip | −1.32 (±1.12) | −1.52 (±1.10) | 0.169a |
Spine | −1.80 (±1.23) | −1.94 (±1.36) | 0.450a |
BMD Z-score | |||
Femoral neck | −0.37 (±0.84) | −0.46 (±0.88) | 0.401a |
Total hip | −0.16 (±1.03) | −0.31 (±0.94) | 0.220a |
Spine | −0.29 (±1.34) | −0.43 (±1.36) | 0.425a |
VitD, ng/ml (n=465) | 21.4 (±9.9) (n=28) | 19.9 (±9.7) (n=437) | 0.431a |
VitD, ng/ml | |||
<20 | 14 (50.0) | 234 (53.5) | 0.715b |
⩾20 | 14 (50.0) | 203 (46.5) | |
PTH, pg/ml (n=203) | 48.7 (±34.0) (n=9) | 65.7 (±58.1) (n=194) | 0.384a |
PTH, pg/ml | |||
⩽72 | 6 (66.7) | 143 (73.7) | 0.640b |
>72 | 3 (33.3) | 51 (26.3) | |
Medication use (N, %) | |||
Topical steroids (>6 months, during 2 years before BMD) | 2 (3.2) | 55 (4.9) | 0.556b |
Systemic steroids (>3 months, during 2 years before BMD) | 2 (3.2) | 96 (8.5) | 0.142b |
Hormone replacement therapy (during 2 years before BMD) | 13 (21.0) | 244 (21.6) | 0.910b |
Vitamin D (during the last 12 months before BMD) | 1 (1.6) | 106 (9.4) | 0.037b |
Bisphosphonates (during 2 years before BMD) | 8 (12.9) | 296 (26.2) | 0.020b |
Bisphosphonates (ever) | 39 (62.9) | 694 (61.4) | 0.808b |
Anticonvulsants (during 2 years before BMD) | 4 (6.5) | 62 (5.5) | 0.745b |
